<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>An increasing number of volunteer unrelated donor bone marrow transplantations (VUD-BMT) are performed every year for <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> due to the availability of a large donor pool </plain></SENT>
<SENT sid="1" pm="."><plain>Here we show the results of 36 VUD transplants from our institution using a chemotherapy-only conditioning regimen comprising <z:chebi fb="0" ids="28901">busulfan</z:chebi> 4 x 4 mg/kg and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> 2 x 60 mg/kg </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received <z:chebi fb="5" ids="28304">heparin</z:chebi> 200 IU/kg bw continuous i.v. infusion starting the day before conditioning until day +30 </plain></SENT>
<SENT sid="3" pm="."><plain>Thirty-four of 36 patients (94%) engrafted and no secondary graft failure was observed </plain></SENT>
<SENT sid="4" pm="."><plain>The two non-engraftments occurred in patients with <z:mp ids='MP_0005481'>CML</z:mp> in <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> with extensive <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 34 engrafted patients (100%) were in complete remission on day +30 as shown by bone marrow biopsy and cytogenetic examinations </plain></SENT>
<SENT sid="6" pm="."><plain>No life-threatening treatment-related morbidity or mortality (TRM) were observed, in particular, no severe <z:e sem="disease" ids="C0948441" disease_type="Disease or Syndrome" abbrv="VOD">veno-occlusive disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e>) of the liver and no fatal pulmonary complication </plain></SENT>
<SENT sid="7" pm="."><plain>Use of G-CSF significantly shortened the time of <z:hpo ids='HP_0001875'>neutropenia</z:hpo> by 5 days </plain></SENT>
<SENT sid="8" pm="."><plain>GVHD prophylaxis consisted of CsA/<z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> with or without MTX </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> GVHD grade II-IV was observed in 18/34 patients (53%) and cGVHD in 12/27 patients (45%), who survived to day +100 </plain></SENT>
<SENT sid="10" pm="."><plain>In seven patients (four with HLA class I or II mismatch) anti-T-lymphocyte globulin (ATG) was added for <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD prophylaxis </plain></SENT>
<SENT sid="11" pm="."><plain>One of seven had aGVHD grade II and none developed grade III to IV GVHD or graft failure </plain></SENT>
<SENT sid="12" pm="."><plain>We conclude that Bu/CY is a feasible, save and sufficiently immunosuppressive regimen for VUD transplantation </plain></SENT>
<SENT sid="13" pm="."><plain>Severe <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD might be avoided by additional use of ATG in GVHD prophylaxis </plain></SENT>
</text></document>